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ABSTRACT
This paper presents a model for assessing the potential effect of an HIV/AIDS vaccine in South
Africa, and for calculating the amount of vaccine that would be required. A number of different
hypothetical vaccine profiles and vaccine distribution strategies are considered. Results suggest that a
sterilising vaccine could reduce the HIV incidence between 2015 and 2025 by up to 50%, while a
disease modifying vaccine would be unlikely to reduce HIV incidence by more than a third. The
effect on AIDS mortality over the same period would be substantially smaller, and it is unlikely that
any preventive vaccine would reduce AIDS mortality by more than 10% between 2015 and 2025.
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1. INTRODUCTION
1.1 South Africa is a country severely affected by HIV/AIDS, with one of the highest
rates of HIV prevalence in the world. In spite of the significant HIV prevention
programmes that have been introduced in South Africa, HIV incidence remains high,
with around 1400 new HIV infections every day (Dorrington et al., unpublished). There
is thus a great need for new, more effective interventions and technologies to limit the
spread of HIV. Much hope has been pinned on the potential development of an
HIV/AIDS vaccine.
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1.2 Mathematical models have been used extensively to demonstrate the potential
benefits from an HIV/AIDS vaccine and to determine which strategies would be most
appropriate for distributing such a vaccine. However, in a recent review of these models,
Rowley (unpublished) has noted that none of the models examines the question of how
differences in vaccine acceptance between sub-populations might influence the effect of an
HIV/AIDS vaccine, and most studies have not adequately considered the range of possible
characteristics the first vaccines may have. With a few exceptions (Garnett, 1998; Stover et
al., unpublished; Davenport et al., 2004), most vaccine models are not age-structured, and
thus cannot be used to predict the effect of limiting vaccination to particular age groups. It
has been suggested that actuaries may have an important role to play in bridging the divide
between epidemiological models of vaccine effects, which make limited allowance for
population dynamics, and age-structured demographic models, which make little
allowance for the effects of disease (Cornall, Chan & Sparks unpublished).
1.3 The objective of this paper is thus to explore the potential effects of an HIV/AIDS
vaccine in South Africa, using an integrated demographic and epidemiological model of
the HIV/AIDS epidemic, developed by the Actuarial Society of South Africa. In addition
to addressing the needs of actuaries for estimates of the future effect of HIV/AIDS
vaccines on levels of mortality and morbidity in South Africa, this paper addresses an
important need for estimates of the amounts of vaccine stock that would be required,
which will be critical in determining the level of vaccine production capacity required and
the level of funding that will be needed in order to support an HIV/AIDS vaccination
programme (Hecht & Suraratdecha, 2006). It also assesses which strategies for vaccine
distribution are likely to be most appropriate in the South African context. Although it is
likely to be several years before an HIV/AIDS vaccine is available for distribution, it is
important that these questions be researched and debated well before a vaccine enters the
mass-production phase.
2. FACTORS AFFECTING THE IMPACT OF AN HIV/AIDS VACCINE
2.1 TIME TO VACCINE DISTRIBUTION
2.1.1 There is currently much uncertainty as to when the first effective
HIV/AIDS vaccine is likely to be ready for distribution. Candidate vaccines have to be
tested in phase I and II trials (safety and immunogenicity trials) and in a phase III
(efficacy) trial before they can be licensed. At present there is only one phase III
HIV/AIDS vaccine trial in progress world-wide, with results expected in 2008/9
(Rodriguez-Chavez et al., 2006). There are approximately 30 phase I and phase II trials
under way, and those that progress to phase III in future will usually require a further
three years until completion of these trials. Discounting the possible success of the
current phase III trial, it therefore seems unlikely that any HIV/AIDS vaccine candidate
would be proven effective before 2010.
2.1.2 Even if a vaccine were proven effective in 2010, several further hurdles
would need to be cleared before the vaccine would be ready for distribution. The vaccine
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would need to be licensed, both by the authorities that monitored the phase III trial and by
the authorities in the country wishing to use the vaccine. It may be necessary to conduct
local efficacy trials, as vaccine efficacy may depend on local HIV strains, local host genetic
profiles and local modes of HIV transmission. For ethical and legal reasons, it may also be
necessary to conduct separate trials in adolescents (WHO-UNAIDS Expert Group, 2005).
It would also be necessary to establish the manufacturing capacity required to produce the
vaccine. Ideally this should start when phase III trials are in progress, but because of the
uncertainty as to whether the vaccines will prove successful, the investment of hundreds of
millions of dollars in setting up this productive capacity is a significant gamble (Collins,
2005). Realistically, the creation of productive capacity would begin only once provisional
results suggest a high level of efficacy. This could significantly delay distribution of the
vaccine, given the five-year lead time typically required for the setting up of such capacity
(International AIDS Vaccine Initiative, unpublished).
2.1.3 Realistically, therefore, it is improbable that an HIV/AIDS vaccine
would be ready for distribution in South Africa much before 2015. The AIDS Vaccine
Advocacy Coalition (2005) emphasises that, because of the many unforeseen complexi-
ties associated with vaccine development, time frames are often not met, and a degree of
conservatism is therefore appropriate in forecasting the likely time to vaccine
distribution.
2.2 VACCINE CHARACTERISTICS
2.2.1 A vaccine may be preventive (of benefit only to individuals who are
HIV-negative at the time of vaccination) or therapeutic (of benefit to individuals who are
HIV-positive at the time of vaccination). For preventive vaccines, which are the focus of
this paper, efficacy has several dimensions. Firstly, the type of protection can be
sterilising (blocking infection) or disease-modifying (reducing viral load and delaying
progression to AIDS in individuals who become infected with HIV after vaccination).
Secondly, efficacy will depend on the cross-reactivity of the immune response, i.e.
whether the vaccine affords protection only against a single HIV subtype or against
multiple subtypes. A third dimension of efficacy is durability, the extent to which the
vaccine provides lasting protection.
2.2.2 The candidate HIV/AIDS vaccines currently being tested can be broadly
divided into those that aim to induce a humoral (neutralising antibody) response, those
that aim to induce a cellular (cytotoxic T-lymphocyte or CTL) response and those that
follow a hybrid approach. Although HIV vaccine research initially focused mainly on
humoral immunity, this approach was not successful, and almost all recent candidates aim
to induce a CTL response (Global HIV/AIDS Vaccine Enterprise, 2005). It therefore
seems probable that the first vaccines distributed will induce cellular rather than humoral
immunity to HIV.
2.2.3 In order to understand the likely characteristics of the first HIV/AIDS
vaccines, it is important to understand the distinction between cellular and humoral
immunity to HIV. It is generally held that a vaccine that induces an HIV-specific CTL
response would probably not prevent HIV infection (Lemckert, Goudsmit & Barouch,
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2004; Morris, Williamson & Vardas, 2001), though studies in non-human primates
suggest it might be disease-modifying (Graham, 2002). A vaccine that induces a humoral
immune response, on the other hand, is more likely to prevent HIV infection, as HIV
antibodies could clear free HIV virions before they enter CD4 cells and replicate.
2.2.4 To date, no HIV/AIDS vaccine candidate has managed to induce a
neutralising antibody response that is broadly cross-reactive. However, a vaccine that
targets a cellular immune response is more likely to protect against multiple subtypes,
since most of these vaccines make use of the highly conserved regions of the HIV
genome, i.e. those regions of the genome that are similar across HIV subtypes. CTL
responses to these highly conserved regions have been shown to occur across a number of
subtypes (Yu et al., 2005). In addition, many of the vaccines that aim to induce a cellular
immune response use genes from more than one subtype.
2.2.5 The evidence to date does not suggest that an HIV/AIDS vaccine would
provide lasting protection. Naturally-occurring HIV-specific immune responses, whether
humoral or cellular, appear to wane in the absence of regular exposure to HIV (Mazzoli et
al., 1999; Kaul et al., 2001), and the same may be true for vaccine-induced HIV-specific
immune responses. It also seems likely that it will be necessary to administer multiple
vaccine doses in order to establish an initial immune response (Suraratdecha & Hecht,
unpublished), and many of the vaccine candidates currently being developed are based on
a ‘prime-boost’ approach, which involves the administration of different vaccines at
intervals of a few weeks or months. The only candidate that has thus far completed
phase III-trial testing consisted of six doses, but this candidate was found not to be
effective (rgp120 HIV Vaccine Study Group, 2005).
2.3 VACCINE DISTRIBUTION STRATEGY
2.3.1 Two types of vaccine distribution strategies are commonly modelled:
‘cohort vaccination’, in which individuals are vaccinated on reaching a certain age, and
‘blanket vaccination’, in which all unvaccinated individuals are vaccinated at a constant
rate (Garnett, 1998). In reality, the strategy that would achieve the most rapid and
extensive vaccine coverage would be ‘mass vaccination’. This is usually once-off,
although ‘pulsed campaigns’ or ‘follow up campaigns’ can involve mass vaccination
every few years. Typically, a special national or regional immunisation day is held, on
which individuals are encouraged to come to a particular vaccination point to be
vaccinated. Following a mass vaccination campaign, vaccine coverage could be
maintained through cohort vaccination.
2.3.2 The focus of this paper is limited to vaccine distribution strategies that
would be appropriate when large amounts of vaccine stock are available. It should be
noted, however, that when the first HIV/AIDS vaccines become commercially available,
they are likely to be expensive and limited in supply. Alternative strategies for
distributing HIV/AIDS vaccine would need to be considered under these circumstances
(Chang, Vitek & Esparza, 2003).
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2.4 RATES OF VACCINE ACCEPTANCE AND SERIES COMPLETION
2.4.1 A number of studies have examined individual willingness to receive a
hypothetical HIV/AIDS vaccine. In developing countries with generalised HIV/AIDS
epidemics, estimates of the proportions of individuals willing to be vaccinated against
HIV lie between 64% and 96%. Rates of acceptance are particularly high in those groups
with high HIV risk profiles: sex workers, truck drivers and military recruits (Jackson et
al., 1995; Hom et al., 1997; Suraratdecha, Ainsworth & Tangcharoensathien, 2002).
Rates of acceptance also appear to be higher at young ages than at old ages, even after
controlling for the individual’s perceived risk of HIV infection (Bishai et al., 2004;
Suraratdecha et al., 2005). The acceptability of HIV/AIDS vaccination does not appear to
be significantly influenced by the efficacy of the vaccine (Forsythe, unpublished; Bishai
et al., 2004; Suraratdecha et al., 2005).
2.4.2 If the HIV/AIDS vaccine consists of more than one dose, not all individu-
als will return to complete the vaccine series. Although South African studies suggest that
more than 80% of vaccine series in children are completed (Durrheim et al., 2001)1, Ameri-
can studies of hepatitis B vaccination in adults suggest much lower series completion
(Zimet et al., 2001; Sellors et al., 1997). As it is highly likely that the first HIV/AIDS vac-
cines will be multi-dose, and the vaccines will be less effective if the series is not completed,
the low rate of series completion typical in adults is a significant cause for concern.
2.5 CHANGE IN BEHAVIOUR AFTER VACCINATION
2.5.1 It is possible that, because of reduced fear of HIV infection or its
consequences, individuals who receive an HIV/AIDS vaccine may increase their level of
sexual risk behaviour after vaccination. In studies that have asked individuals whether
they would increase the amount of unprotected sex they have after HIV/AIDS
vaccination, between 5% and one third report they would (Jackson et al., 1995;
Suraratdecha et al., 2005; Hom et al., 1997). This change in behaviour appears to be more
likely if the vaccine is highly effective than if the vaccine is only partially effective
(Suraratdecha et al., 2005). However, these reports can provide an indication only of
individuals’ intended sexual behaviour after vaccination, and it remains uncertain what
the actual extent of behaviour change would be.
2.5.2 Another possible change in behaviour after HIV/AIDS vaccination is
reduced seeking of voluntary counselling and testing (VCT). Individuals may feel less need
to seek VCT if they regard themselves as being protected against HIV. It is also likely that if
the HIV/AIDS vaccine is highly immunogenic, it will induce HIV-specific antibodies,
which will make standard antibody tests unreliable as measures of true HIV status.
Vaccinated individuals seeking VCT would therefore have to be tested using polymerase
chain reaction (PCR) or other tests, which are more expensive and time-consuming. This
too could act as a disincentive for vaccinated individuals to seek VCT.
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1 cf. also Department of Health (1999) South Africa Demographic and Health Survey 1998: Full
Report.
3. METHOD: THE ASSA2002 VACCINE MODEL
To assess the potential effect of HIV/AIDS vaccines in South Africa, a model was
developed by adapting a C++ version of the ASSA2002 AIDS and Demographic model
(Johnson, Dorrington & Matthews, unpublished). The more recent ASSA2003 version
has not been used for this paper, as it was still being developed at the time that work
started on the ASSA2002 Vaccine model. However, the ASSA2003 version produces
similar results to the ASSA2002 version, and the two versions are structurally identical.
The use of the ASSA2003 model as the basis for the vaccine model would therefore not
substantially change the results presented in this paper. The ASSA2002 Vaccine model
has been programmed both in C++ and in Excel/VBA, and the C++ and Excel/VBA
versions produce identical results. The sections that follow describe the model structure,
the choice of parameters and the scenarios considered in section 4.
3.1 BACKGROUND: THE ASSA2002 MODEL
3.1.1 The ASSA2002 AIDS and Demographic model is a model of the South
African HIV/AIDS epidemic, developed under the auspices of the Actuarial Society of
South Africa (ASSA). The sexual transmission of HIV is modelled by splitting the
population aged 14 to 59 into four ‘risk groups’, which have different risks of HIV
infection. The ‘PRO’ group represents sex workers and their frequent clients, while the
‘STD’ group represents individuals who are regularly infected with sexually transmitted
diseases (STDs). The ‘RSK’ group represents individuals who are at risk of infection,
although not falling into either of the previous two categories. Finally, the ‘NOT’ group
represents individuals whose risk of infection is negligible, either because they are not
sexually active or because they are in long-term, mutually monogamous relationships. All
individuals over the age of 59 are assumed not to be at risk of acquiring HIV. Children
under the age of 14 are also assumed not to be at risk of acquiring HIV, except through
mother-to-child transmission (which is assumed to occur at or before birth, or through
breastfeeding in the 12 months after birth).
3.1.2 After acquiring HIV, adults are assumed to progress through four stages
of infection before either dying from AIDS or starting antiretroviral treatment. These four
stages correspond to the four stages of the WHO Clinical Staging System. In addition to
allowing for the effects of antiretroviral treatment, the model allows for the effect of four
types of prevention strategy: improved treatment of STDs, social marketing (information
and education campaigns), VCT and prevention of mother-to-child transmission
(PMTCT).
3.1.3 The ASSA2002 model, user guide and supporting documentation are
freely available from www.assa.org.za/aids.
3.2 MODELLING VACCINE CHARACTERISTICS
3.2.1 In order to model vaccine characteristics, the ASSA2002 Vaccine model
splits the population into four classes:
– class 1: unvaccinated individuals;
– class 2: vaccinated individuals who are fully protected against HIV;
SAAJ 7 (2007)
54  THE POTENTIAL EFFECT OF AN HIV/AIDS VACCINE IN SOUTH AFRICA
– class 3: vaccinated individuals who are partially protected against HIV; and
– class 4: individuals who have been vaccinated but are currently not protected.
3.2.2 The potential movements between the classes are illustrated in Figure 3.1.
On being vaccinated, specified proportions of vaccinated individuals are moved into
classes 2 to 4, depending on the efficacy of the vaccine and the type of immunity it
induces. Individuals who are vaccinated after HIV infection are assumed to derive no
benefit from the vaccine. Individuals who are initially protected by the vaccine can lose
protection over time, and individuals are assumed to progress from fully protected to
partially protected, and from partially protected to unprotected. No allowance is made for
revaccination, either before or after the protection has waned.
Figure 3.1. Possible movements between vaccination classes
3.2.3 Individuals who are in the ‘fully protected’ class are by definition not at
risk of HIV infection. Individuals in the ‘partially protected’ class may be at a reduced
risk of infection, and may also be at a reduced risk of progression to AIDS if they become
infected with HIV after vaccination. Individuals in the ‘unprotected’ class, however, are
protected neither against infection nor against progression to AIDS.
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3.2.4 Because of the uncertainty regarding the likely characteristics of the first
HIV/AIDS vaccine, four different hypothetical vaccines are considered in section 4. The
characteristics of these four hypothetical vaccines are summarised in Table 3.1. These
vaccine parameters were selected to represent a range of plausible vaccine characteristics,
and do not necessarily represent actual vaccines being developed. The efficacy rates of
the different vaccines are expressed in terms of:
– the reduction in susceptibility to infection, VES;
– the reduction in the level of HIV infectiousness during stages 1 and 2 of disease, VEI;
– the reduction in the rate of progression to AIDS, VEP; and
– the mean duration of protection, .
It is assumed that all four vaccines consist of a series of three doses. (Although it is not
clear how many doses will comprise the first HIV/AIDS vaccine, a three-dose vaccine is
considered more likely than the conventionally assumed single-dose vaccine—cf.
¶2.2.5.) All individuals who receive the full series of doses are moved into the ‘partially
protected’ class. Of individuals who do not receive the full series of doses, half are moved
into the ‘partially protected’ class and the remaining half are moved into the ‘unprotected’
class. The efficacy parameters in Table 3.1 relate only to adults in the partially protected
class (zero efficacy is assumed for the unprotected class).











A 0,00 0,83* 0,84 10
B 0,30 0,83* 0,84 10
C 0,30 0,83* 0,84 
D 0,95 0,00 0,00 10
*The value shown is an average; the VEI parameter depends on the assumed exponential increase in
infectiousness per unit increase in the logarithm of the viral load, which varies in the uncertainty
analysis.
3.2.5 For vaccines A, B and C, which are disease-modifying, the VEI and VEP
parameters are consistent with what one would expect for an HIV vaccine that reduces the
logarithm of the HIV viral load by two units, a reduction that would appear to be
achievable on the basis of candidate vaccines tested in non-human primates (Shiver et al.,
2002; Barouch et al., 2000; Egan et al., 2000). These VEI and VEP parameters are derived
from estimates of the increase in HIV infectiousness per unit increase in the logarithm of
the HIV viral load, I, and the increase in the rate of progression to AIDS per unit increase
in the logarithm of the HIV viral load, P. Uncertainty analysis of the ASSA2002 model
suggests that the distribution of plausible I values has a mean of 152%, and a 95% range
of 76 to 270% (Johnson, Dorrington & Matthews, op. cit.). In the uncertainty analysis of
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the ASSA2002 Vaccine model, this distribution is used to simulate the distribution of
possible VEI parameters, by calculating VEI as:






3.2.6 This reduction in infectiousness is assumed to apply only when the
infected individual is in WHO clinical stages 1 and 2, after which the protection provided
by the vaccine is assumed to be lost. Similarly, the VEP parameter is calculated as:






3.2.7 P is assumed to be 150% (O’Brien et al., 1998; Lyles et al., 1999; Hubert
et al., 2000), which gives the VEP value of 0,84 in Table 3.1. On the assumption that the
effect of the vaccine is limited to WHO stages 1 and 2, the median terms spent in stages 1
and 2 are set to be 191% greater in vaccinated individuals than in unvaccinated individu-
als, which is consistent with the VEP value of 0,84. (For a more detailed explanation, see
Johnson & Dorrington (unpublished, p.73).)
3.3 MODELLING VACCINE TIMING AND DISTRIBUTION
3.3.1 For the purpose of the analysis that follows, we consider the relatively
optimistic scenario in which the first HIV/AIDS vaccine is introduced in 2015, and there
is sufficient vaccine stock available to immunise a significant proportion of the South
African population. Four potential strategies for distributing the vaccine are considered,
and these are described in Table 3.2. All four strategies are combinations of mass
vaccination, childhood vaccination and school-based vaccination. The first represents the
most extensive vaccination that could be achieved. Strategies 2 and 3 target those sections
of the population with higher levels of sexual activity. Strategy 4 is similar to the
distribution strategy suggested at a recent WHO consultation (WHO-UNAIDS Expert
Group, 2005). The periods over which these distribution strategies are implemented are
shown in the last column.
Table 3.2. Vaccine distribution strategies
Strategy number Type of distribution strategy Ages Distribution period
1 Mass vaccination 0 59 2015
Childhood vaccination 3 months 2015 2025
2 Mass vaccination 15 49 2015
School based vaccination 15 2015 2025
3 Mass vaccination 15 24 2015
School based vaccination 15 2015 2025
4 School based vaccination 15 2015 2025
Childhood vaccination 3 months 2015 2025
3.3.2 Vaccine distributed by mass vaccination and childhood vaccination is
assumed to be offered to all individuals in the population in the relevant age groups.
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Vaccine distributed by school-based vaccination is assumed to be offered only to the 95%
of 15-year olds who are in school.2
3.4 MODELLING VACCINE ACCEPTANCE AND SERIES COMPLETION
3.4.1 On the basis of the studies reviewed in ¶2.4.1, vaccine acceptance in the
14-to-59 age range is assumed to depend on both age and risk group, but not on vaccine
efficacy. For each combination of age band and risk group, the probability of acceptance
is simulated using a beta distribution. The means and standard deviations of these
distributions are shown in Table 3.3. To ensure that for each model simulation, the rates
of acceptance in different age and risk groups are consistent with one another, the same
uniform (0, 1) random variable, U1, is used to sample from each inverted cumulative beta
distribution. The sensitivity analysis therefore examines the relationship between model
outputs and the U1 random variable.
Table 3.3. Means (and standard deviations) of the beta distributions
used to simulate the probability of vaccine acceptance
Age group Risk group
PRO STD RSK NOT
14 to 24 0,98 (0,01) 0,95 (0,02) 0,90 (0,03) 0,80 (0,05)
25 to 34 0,95 (0,02) 0,90 (0,03) 0,85 (0,04) 0,75 (0,06)
35 to 44 0,85 (0,04) 0,80 (0,05) 0,75 (0,06) 0,65 (0,08)
45 to 59 0,75 (0,06) 0,70 (0,07) 0,65 (0,08) 0,55 (0,09)
3.4.2 Vaccine acceptance below age 12 would require parental consent, which
is assumed to be given in 98% of cases (Hutchins et al., 1993). (Current South African
legislation requires that all children under the age of 14 receive parental consent prior to
any medical treatment, but this age of consent is likely to be lowered to 12 in the near
future.3) Since rates of vaccine series completion tend to be high in childhood, and since
high rates of follow-up are possible if vaccines are distributed through schools, both
childhood vaccination and school-based vaccination are assumed to be associated with
high rates of series completion. In both cases, the probability of completing the series of
three doses after receiving the first is simulated using a beta distribution with mean 0,85
and standard deviation 0,05. The probability of series completion under mass vaccination
is simulated to be lower, using a beta distribution with mean 0,60 and standard deviation
0,10. For each simulation, the same uniform (0, 1) random variable, U2, is used to
simulate both completion probabilities.
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2 Statistics South Africa (2005) General household survey, July 2004. Available:
http://www.statssa.gov.za/Publications/P0318/P0318July2004.pdf
3 Ann Strode, University of KwaZulu Natal, personal communication
3.5 MODELLING EFFECTS OF VACCINE ON BEHAVIOUR
3.5.1 In the ASSA2002 Vaccine model, change in sexual behaviour in the
HIV-negative population (‘behavioural inhibition’) is assumed to be the result of social
marketing programmes. HIV-negative individuals who are regularly exposed to social
marketing programmes and have easy access to condoms are assumed to increase condom
usage. In response to HIV vaccines, however, a proportion of these individuals revert to
their former sexual practices, using condoms to the same extent as in the absence of social
marketing programmes. This proportion is simulated using a beta distribution, with mean
0,25 and standard deviation 0,08 in the case of vaccines A to C, and with mean 0,5 and
standard deviation 0,15 in the case of vaccine D. It is thus assumed that a vaccine that is
highly effective in preventing HIV would be associated with greater reductions in
condom usage. A more detailed mathematical explanation of the modelling of the change
in sexual behaviour and HIV transmissibility after vaccination is given in Johnson &
Dorrington (op. cit.).
3.5.2 Allowance is also made for reductions in utilisation of VCT services by
individuals who have been vaccinated. The reduction in the annual probability of seeking
VCT is simulated using a beta distribution, with mean 40% and standard deviation 20% in
the case of vaccines A to C, and with mean 80% and standard deviation 10% in the case of
vaccine D.
3.6 UNCERTAINTY ANALYSIS AND SENSITIVITY ANALYSIS
3.6.1 Uncertainty regarding vaccine parameters is modelled using Monte
Carlo simulation, parameter values being sampled from the beta distributions described
above. 500 combinations of these vaccine parameters are randomly generated. These
parameter combinations are then randomly paired with 500 combinations of other
ASSA2002 parameters, generated in an earlier uncertainty analysis (Johnson, Dorrington
& Matthews, op. cit.). These other parameters determine HIV survival in the absence of
treatment, and sexual behaviour and probabilities of HIV transmission in the absence of
prevention programmes. Allowance has also been made for uncertainty regarding the
future availability of antiretroviral treatment and the effectiveness of PMTCT
programmes. The uncertainty analysis presented here therefore reflects both uncertainty
with respect to HIV/AIDS vaccine parameters and uncertainty with respect to basic HIV
epidemiology.
3.6.2 For each of the vaccine-distribution scenarios and hypothetical vaccines,
results of the uncertainty analysis are presented in terms of means (of the results
generated using the 500 different parameter combinations) and 95% prediction intervals
(2,5 and 97,5 percentiles of the 500 result sets). Sensitivity analysis is conducted by
scatterplot and by calculation of correlation coefficients.
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4. RESULTS
4.1 AMOUNT OF VACCINE REQUIRED
4.1.1 The projected numbers of individuals vaccinated between 2015 and 2025
are shown in Figure 4.1(a). Strategy 1 (vaccinating the population under the age of 60 in
2015 and infants born in each subsequent year) would require the most vaccine. Of the
46,5 million individuals who would be vaccinated under this strategy (95% interval:
42,8–49,9 million), it is expected that roughly 36,9 million (95% interval: 33,2–
40,2 million) would be vaccinated in 2015 and the balance would be infants vaccinated in
subsequent years. Strategies 2 and 3 would also require very large initial amounts of
vaccine stock, as shown in Figure 4.1(c). Mass vaccination of 15- to 49-year olds in 2015
(strategy 2) would result in 20,3 million vaccinations (95% interval: 17,4–22,7 million) in
2015, while mass vaccination of 15- to 24-year olds in 2015 (strategy 2) would require
8,2 million vaccinations (95% interval: 7,4–8,9 million) in that year. Although strategy 4
would also require a large total investment (18,5 million vaccinated individuals,
95% interval: 17,4–19,6 million), this would be more evenly spread over the 2015–2025
period. Only 1,7 individuals would be vaccinated in 2015 (95% interval: 1,6–1,8 million)
and similar numbers would be vaccinated in each subsequent year (Figure 4.1(e)).
4.1.2 Figures 4.1(b), (d) and (f) show the total doses consumed for each of the
four strategies, on the assumption of a vaccine consisting of three doses. The numbers of
vaccine doses consumed are between two and three times the total numbers of individuals
vaccinated.
4.2 POTENTIAL EFFECTS OF AN HIV/AIDS VACCINE
4.2.1 The percentage reduction in new HIV infections between 2015 and 2025
is shown in Figure 4.2(a), for all hypothetical vaccines and all vaccine distribution
strategies. As might be expected, the reduction in new infections is greatest for vaccine D
and smallest for vaccine A. Strategy 2 is marginally more effective than strategy 1, as
there are more short-term benefits to vaccinating individuals in early adolescence than
there are to vaccinating children, whose vaccine-induced immune responses may wane
by the time they become sexually active (the exception is vaccine C, which is assumed to
provide lifelong protection). Strategy 4 is likely to be the least effective of the four
strategies considered, as it results in protection of only a small proportion of the sexually
active population. Strategy 3 can be expected to be 10% to 20% less effective than
strategy 2 in preventing HIV, though this strategy requires considerably less vaccine.
4.2.2 Figure 4.2(b) shows the reduction in AIDS deaths between 2015 and
2025, as a result of vaccination. Reductions in AIDS mortality are significantly smaller
than reductions in new HIV infections. Although there are significant differences
between the vaccines in terms of the extent to which they reduce HIV incidence,
differences in terms of reduced AIDS mortality are less substantial. Vaccines A, B and C
are less effective than vaccine D in preventing HIV, but are nevertheless effective in
delaying disease progression, and thus there is relatively little difference between the
vaccines in terms of reduced AIDS mortality.
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4.2.3 Trends in the annual number of new HIV infections are shown in
Figure 4.34 for three scenarios: a ‘no vaccine’ scenario (a), a scenario in which vaccine B
is distributed in accordance with strategy 2 (b), and a scenario in which vaccine D is
distributed in accordance with strategy 2 (c). Vaccine B would reduce HIV incidence
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(a) Total vaccinated individuals, 2015–25
Strategy 1 Strategy 2 Strategy 3 Strategy 4
.
(c) Vaccinated individuals, 2015
Strategy 1 Strategy 2 Strategy 3 Strategy 4
.
(b) Total vaccine consumption, 2015–25
Strategy 1 Strategy 2 Strategy 3 Strategy 4
.
(d) Vaccine consumption, 2015
Strategy 1 Strategy 2 Strategy 3 Strategy 4
.
Figure 4.1. Numbers of vaccinated individuals and vaccine doses, 2015–2025
(e) Average annual vaccinated individuals,
2016–25
Strategy 1 Strategy 2 Strategy 3 Strategy 4
.
(f) Average annual vaccine consumption,
2016–25
Strategy 1 Strategy 2 Strategy 3 Strategy 4
.
4 The Excel files used to generate this figure and other figures are available from the
authors on request.
modestly at first (fewer primary infections), but would have a more significant effect on
HIV incidence over the longer term (fewer secondary infections, due to reduced
infectiousness of individuals infected after vaccination). In contrast, vaccine D would
reduce HIV incidence very significantly in 2015, but the preventive benefit of the vaccine
(relative to the ‘no vaccine’ scenario) would wane over time, as vaccinated individuals
lose their immunity.
4.2.4 For the same three scenarios, trends in total HIV infections are shown in
Figures 4.3(d)–(f). While vaccine D would lead to a significant drop in HIV prevalence
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Figure 4.2. Percentage reduction in new HIV infections and AIDS deaths
after 2015, the reduction in prevalence would be considerably smaller for vaccine B.
Reductions in AIDS mortality would be less noticeable over the short term. Figures
4.3(g)–(i) show that for both vaccine B and vaccine D there would be slight reductions in
annual numbers of AIDS deaths after 2015.
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Figure 4.3. Trends in HIV incidence, HIV prevalence and AIDS mortality,
with and without vaccine*
*Vaccine is assumed to be distributed in accordance with strategy 2. Solid outer lines represent
95% prediction intervals (2,5 and 97,5 percentiles of model outputs). Interval between 40 and 60
percentiles.  Intervals between 30 40 and 60 70 percentiles.  Intervals between 20 30 and
70 80 percentiles.  Intervals between 10 20 and 80 90 percentiles.
(h) AIDS deaths, vaccine B (i) AIDS deaths, vaccine D
4.3 EFFICIENCY OF VACCINE DISTRIBUTION STRATEGIES
Figure 4.4 compares the various vaccines and vaccine distribution strategies in
terms of HIV infections averted per vaccinated individual, over the 2015–2025 period.
Strategy 3 is likely to be the most efficient strategy, in terms of preventing HIV, as it is the
strategy that targets the group with the highest incidence of HIV (15- to 24-year-olds).
4.4 CORRELATES OF VACCINE CONSUMPTION AND EFFICIENCY
4.4.1 Correlations between total doses consumed under strategy 2 and
measures of vaccine acceptance and series completion are shown in Figure 4.5. As
explained in section 3.4, the measures of vaccine acceptance (U1) and series completion
(U2) are the uniform (0, 1) random variables used to simulate the vaccine acceptance and
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Figure 4.4. HIV infections averted, per individual vaccinated (2015–2025)
completion rates. Vaccine consumption is strongly positively related to the measure of
vaccine acceptance (r = 0,73, p < 0,001), and is also strongly correlated with the measure
of series completion (r = 0,65, p < 0,001).
4.4.2 A number of factors influence the efficiency of the vaccine distribution
strategy. Figure 4.6 shows the correlation between the numbers of infections averted per
vaccination and various parameters, for vaccine B when distributed in accordance with
strategy 2. The parameter with which the number of infections averted per vaccination is
most strongly correlated is the proportion of the initial sexually active population in the
RSK group (r = 0,55, p < 0,001). This is because the incidence of HIV is dependent
mainly on the size of the RSK group in the late stages of the epidemic, when there are few
HIV-susceptible individuals remaining in the PRO and STD groups. The number of
infections averted per individual vaccinated is also strongly associated with the increase
in HIV infectiousness per unit increase in the logarithm of the viral load (VL) (r = 0,18,
p < 0,001). This is partly due to the strong positive correlation between the effect of viral
load on HIV infectiousness and HIV incidence in the later stages of the HIV/AIDS
epidemic, when average viral-load levels are higher. It is also partly due to the fact that
VEI increases as I increases.
4.4.3 Figure 4.6 also shows that the number of infections averted per
vaccinated individual is likely to be significantly negatively related to the reversal of
improvements in condom usage after vaccination (r = –0,26, p < 0,001). If a straight line
is fitted through the scatterplot in Figure 4.6(c), the predicted number of infections
averted when there is a 50% reversal of behavioural inhibition is 23% less than the
predicted number of infections averted if there is no reversal of behavioural inhibition.
The extent to which vaccinated individuals reduce their utilisation of VCT services is also
significantly correlated with the efficiency of the vaccine in preventing HIV, though not
as significantly as the reversal of behavioural inhibition (r = –0,15, p < 0,001). Although
not shown in Figure 4.6, there is also significant negative correlation between the number
of infections averted per vaccinated individual and the vaccine acceptance parameter U1
(r = –0,22, p < 0,001), which indicates that there are likely to be diminishing marginal
returns associated with HIV/AIDS vaccination programmes. The series-completion
parameter U2 is strongly positively associated with the number of infections averted
per vaccinated individual (r = 0,40, p < 0,001).
4.4.4 The potential negative effect of reductions in condom usage on the
preventive benefit of a vaccine is a cause for concern. Table 4.1 shows the correlation
coefficients between the infections averted per vaccination and the reversal of
behavioural inhibition, for each of the hypothetical vaccines and vaccine distribution
strategies. From this it is clear that reversals of behavioural inhibition have the most effect
when the vaccine reduces susceptibility to HIV by only a small degree and the duration of
protection provided by the vaccine is short (vaccines A and B). The effect of reversal of
behavioural inhibition appears to be similar for each of the vaccine distribution strategies.
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Table 4.1. Correlation coefficients between infections averted
per vaccinated individual and reversal of behavioural inhibition
Vaccine distribution strategy
1 2 3 4
Vaccine A 0,38 0,35 0,37 0,44
Vaccine B 0,27 0,26 0,29 0,32
Vaccine C 0,16 0,17 0,18 0,18
Vaccine D 0,22 0,20 0,24 0,21
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Figure 4.6. Correlates of infections averted per vaccination (vaccine B, strategy 2)
5. DISCUSSION
5.1 PROSPECTS FOR REDUCTIONS IN HIV INCIDENCE AND AIDS
MORTALITY
5.1.1 Although it is widely believed that the development of an effective
HIV/AIDS vaccine would be a deus ex machina, the reality is likely to be different. It is
likely that the first vaccine will be disease-modifying rather than sterilising, and this
analysis has shown that such a vaccine would be unlikely to reduce HIV incidence by
more than a third over the 2015–2025 period. Other model-based evaluations have
suggested that a vaccine that reduces susceptibility to HIV by more than 90% could
eradicate the HIV/AIDS epidemic (Anderson & Garnett, 1996; Blower & McLean,
1994). In this analysis, however, it has been shown that vaccine D (which reduces
susceptibility to HIV by 95%) is unlikely to reduce the total number of new HIV
infections by more than 50%, even with the most extensive vaccine distribution
programmes. This is partly because the model assumes a proportion of individuals
decline the offer to be vaccinated, even though they are at risk of acquiring HIV. It is also
partly because of the assumption that a significant proportion of individuals receiving the
vaccine through a mass vaccination programme would not return to complete the vaccine
series, and the vaccine would be less effective in these individuals. In addition, it is
assumed that the protection provided by the vaccine wanes over time, and that individuals
who have been vaccinated will tend to revert to the level of sexual risk behaviour they
would have engaged in during the pre-AIDS era. Allowing for these considerations, it
seems highly unlikely that an HIV/AIDS vaccine would by itself lead to the eradication of
the HIV/AIDS epidemic.
5.1.2 Reversal of behavioural inhibition in vaccinated individuals has the
potential to reduce significantly the effect of a vaccine that is primarily disease-
modifying. If, however, the vaccine induces a high level of sterilising immunity, the
effect of the vaccine is significantly less sensitive to the reversal of behavioural
inhibition, as other studies have shown (Bogard & Kuntz, 2002; Nagelkerke & De Vlas,
unpublished). This suggests that the poorer the ability of the vaccine to induce sterilising
immunity, the greater will be the need for education promoting continued risk-reduction
behaviour in vaccinated individuals. The extent to which VCT utilisation changes after
vaccination could also significantly affect the preventive benefit of the vaccine. This is a
parameter that has not been explored in previous research on the potential effect of
HIV/AIDS vaccines.
5.1.3 This analysis suggests that even the most effective vaccines would be
unlikely to reduce AIDS mortality by more than 10% over the 2015–2025 period. This
can be explained by the fact that most of the AIDS deaths that are expected to occur over
that period are the result of HIV infections occurring prior to 2015, which would not be
prevented by the first vaccines. More substantial reductions would be expected over the
longer term, however. It is possible that a vaccine might achieve more immediate
reductions in AIDS mortality if the vaccine is therapeutic, but it is not clear whether the
first vaccines are likely to have therapeutic properties (Peters, 2002).
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5.2 VACCINE DISTRIBUTION STRATEGIES AND VACCINE REQUIREMENTS
5.2.1 Of the four strategies considered, the most effective strategy would
probably be to conduct mass vaccination of 15- to 49-year olds in 2015, together with
vaccination of high-school learners aged 15, in 2015 and subsequent years. However, if
there is not sufficient vaccine available in 2015 to vaccinate 20 million people, a suitable
alternative may be to limit the initial mass vaccination to 15- to 24-year olds, which would
require enough vaccine for only 8 million individuals in 2015. This strategy would avert
10 to 20% fewer infections than the first strategy, but would ensure a much more efficient
use of the limited vaccine supply.
5.2.2 The strategy suggested at a recent WHO consultation, namely to
vaccinate all newborn infants as well as all children entering adolescence (WHO-
UNAIDS Expert Group, op. cit.), is likely to be neither effective nor efficient, relative to
the other strategies considered. It may, however, prove to be more effective over the
longer term, as protection may be boosted considerably when children who have been
vaccinated in infancy are revaccinated in early adolescence. This strategy would also
have the advantage of requiring a less substantial initial expenditure on vaccine in 2015,
but would require more vaccine than the other strategies in each subsequent year.
5.2.3 When estimating the total number of vaccine doses required in South
Africa, the estimates of total vaccine doses consumed should be increased to allow for
wastage. Wastage rates of 30 to 40% have been measured in mass vaccination
programmes for measles in South Africa (Uzicanin et al., 2004). Assuming a wastage rate
of 35% for a three-dose HIV/AIDS vaccine, the numbers of vaccine doses required over
the 2015–2025 period would be 155 million for strategy 1 (95% interval: 133–
176 million), 92 million for strategy 2 (77–108 million), 54 million for strategy 3 (46–
60 million) and 69 million for strategy 4 (63–74 million).
5.3 STRENGTHS AND LIMITATIONS OF THE ASSA2002 VACCINE MODEL
5.3.1 The ASSA2002 Vaccine model improves on earlier estimates of vaccine
requirements (Hecht & Suraratdecha, 2006) by allowing explicitly for rates of vaccine
acceptance and rates of series completion in calculating the number of vaccine doses
required. With the exception of the study of Esparza et al. (2003), other estimates of
vaccine requirements have not taken these factors into consideration explicitly. The
model also improves on earlier estimates of vaccine requirements by using projections of
the future population (taking into account changing population size and the effect of
AIDS up to the time that the vaccine is distributed) rather than using a fixed population set
at current estimates. Being a combined demographic and epidemiological model, the
ASSA2002 Vaccine model is also particularly useful in assessing the effect of restricting
vaccine distribution to particular age groups and risk groups.
5.3.2 With a few exceptions (Davenport et al., 2004; Barth-Jones et al.,
unpublished; Blower et al., 2001), most model-based evaluations of vaccine effect have
not included prediction intervals or plausibility bounds around model estimates. The
ASSA2002 Vaccine model integrates both uncertainty regarding basic HIV
epidemiology and uncertainty regarding vaccine parameters, to produce 95% prediction
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intervals around all model estimates. This is particularly important when making long-
term projections, which are shown to be subject to extreme uncertainty.
5.3.3 A key limitation of the ASSA2002 Vaccine model is that it does not
allow for the potential effects of revaccination. If vaccine protection wanes, as is assumed
in the cases of vaccines A, B and D, it may be necessary to revaccinate individuals every
few years. Because revaccination is likely to become particularly important in assessing
the effect of an HIV/AIDS vaccine over the longer term, the focus of this analysis has
been deliberately restricted to the 2015–2025 period. There is a need to examine the
potential effects of vaccine distribution strategies beyond the 2025 horizon, and it would
therefore be useful to adapt the model to allow for the effects of revaccination.
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